These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 1519927

  • 1. [Pharmacokinetics and toxicological study on the intraperitoneal administration of cisplatin and etoposide in gynecological malignancies].
    Fujimoto R, Yanagawa Y, Yamada T, Ueki K, Takahara T, Kumagai K, Okamura S, Ueki M, Sugimoto O.
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1843-9. PubMed ID: 1519927
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
    Shimizu A, Ookubo K, Hasegawa J, Endoh T, Fujiwara O, Yoda A, Okuyama D, Narabayashi A, Kimura T, Takahashi J, Notake Y.
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
    Desoize B, Maréchal F, Cattan A.
    Ann Biol Clin (Paris); 1993 Oct; 51(2):125-8. PubMed ID: 8214810
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer.
    Tsujitani S, Watanabe A, Abe Y, Maehara Y, Sugimachi K, Kaibara N.
    Anticancer Res; 1993 Oct; 13(6B):2497-9. PubMed ID: 8135489
    [Abstract] [Full Text] [Related]

  • 9. [The value of a Tenckhoff catheter in ovarian cancer].
    Kato N, Arakawa A, Yasui Y, Suzumori K, Suzumori K, Yagami Y.
    Gan To Kagaku Ryoho; 1991 May; 18(6):1025-30. PubMed ID: 2029187
    [Abstract] [Full Text] [Related]

  • 10. [Intraperitoneal chemotherapy of CDDP and etoposide in patients with advanced ovarian cancer].
    Hirashima Y, Shimura T, Tanaka Y, Demukai H, Kubota T, Kobayashi T, Suzuki A.
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1321-6. PubMed ID: 8346930
    [Abstract] [Full Text] [Related]

  • 11. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL.
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [Abstract] [Full Text] [Related]

  • 12. [Intraperitoneal (i.p.) chemotherapy in the management of ovarian cancer--pharmacokinetics and methods of sequential i.p. chemotherapy].
    Noda T, Adachi S, Yamamoto T, Hirooka C, Kiyozuka Y, Adachi S, Oku M, Ichijo M.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1561-8. PubMed ID: 2389949
    [Abstract] [Full Text] [Related]

  • 13. Pharmacologic study of etoposide and cisplatin by the intraperitoneal route.
    O'Dwyer PJ, LaCreta F, Hogan M, Rosenblum N, O'Dwyer JL, Comis RL.
    J Clin Pharmacol; 1991 Mar; 31(3):253-8. PubMed ID: 2019667
    [Abstract] [Full Text] [Related]

  • 14. [Analysis of side effects of a combination chemotherapy of cisplatin and adriamycin in gynecological malignancies: comparison between intravenous and intraarterial administration].
    Kawagoe K, Tsunoda H, Iijima S, Yokota H, Shigemitsu S.
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):452-7. PubMed ID: 6538404
    [Abstract] [Full Text] [Related]

  • 15. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
    Muggia FM, Groshen S, Russell C, Jeffers S, Chen SC, Schlaerth J, Curtin J, Morrow CP.
    Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
    Minami H, Horio Y, Sakai S, Saka H, Shimokata K.
    Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G, Beaujard A, Garbit F, Chaduiron-Faye C, Guillaumont M, Gilly F, Baltassat P, Bressolle F.
    Anticancer Res; 2002 Dec; 22(2B):1329-36. PubMed ID: 12168946
    [Abstract] [Full Text] [Related]

  • 18. Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
    Canal P, de Forni M, Chatelut E, Chevreau C, Johnson NP, Houin G, Bugat R.
    Acta Med Austriaca; 1989 Dec; 16(3-4):84-6. PubMed ID: 2609919
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
    Han GR, Cai GF.
    Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
    [Abstract] [Full Text] [Related]

  • 20. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
    Kitada M, Sawaragi I.
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):87-91. PubMed ID: 8546476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.